Surgical procedures constitute one of the most capital- and labour-intensive facets of contemporary healthcare, with annual global totals surpassing 300 million interventions [1] . Rising procedural complexity, reflected in rapid technological advances, refined surgical techniques, and a broader spectrum of patient comorbidities, challenges the applicability of standard health economic evaluation frameworks. Conventional decision-analytic models typically assume homogeneous patient pathways and fixed resource utilisation, omissions that can skew cost-effectiveness conclusions in the surgical context. The launch of TabPFN, the first transformer-based foundation model specifically designed for tabular datasets, presents a promising methodological advance that can mitigate these shortcomings [2] . Distinct from traditional algorithms that demand extensive feature engineering and hyperparameter tuning, TabPFN leverages in-context learning to achieve generalisable inference, thereby accommodating the sparse or highly varied datasets that frequently characterise surgical health economics.

Current economic evaluations in surgical domains continue to depend heavily on traditional statistical approaches and first-generation machine learning algorithms. Such methods frequently falter when confronted with the fragmented, multidimensional, and context-sensitive characteristics of surgical datasets [3] . These limitations are compounded by the dual imperatives of generating clinically interpretable predictions and accommodating the heterogeneity of patient cohorts, surgical techniques, and institutional protocols. TabPFN, with its recently developed architecture, is designed to address these challenges in a cohesive manner; it offers robust performance even on limited sample sizes, accommodates heterogeneous variable types, naturally handles missing data, and captures intricate feature interactions without the need for extensive engineering. We therefore argue that TabPFN could catalyse a substantive reorientation in the economics of surgical care. Its contributions are likely to transcend modest improvements in accuracy, paving the way for modelling frameworks that were previously stymied by data scarcity and prohibitive computational demands.

This paper adopts a narrative review approach to assess the potential of TabPFN in surgical health economics. Rather than undertaking a formal systematic mapping of health economic domains, we focus on synthesising theoretical insights, technical features, and existing literature to construct a forward-looking analytical framework. To ensure transparency of evidence synthesis, the literature search encompassed databases including PubMed, Scopus, and Web of Science, covering publications from January 2010 to February 2025. Search terms combined “surgery”, “health economics”, “machine learning”, and “TabPFN” with Boolean operators. Inclusion criteria prioritised peer-reviewed English-language studies that reported quantitative or methodological findings relevant to surgical economic evaluations or tabular AI models. Grey literature and non-peer-reviewed preprints were excluded unless they contained seminal methodological innovations.

TabPFN represents a foundational shift in tabular data modelling through its use of transformer-based architectures and in-context learning, enabling high performance without task-specific training [10] . As illustrated in Figure 2 , it addresses several long-standing challenges in healthcare analytics. Comparative evaluations demonstrate that TabPFN achieves predictive accuracies of 3% - 8% higher than leading tree-based models such as XGBoost and LightGBM on benchmark healthcare datasets, while requiring under one second of inference runtime for small- to medium-sized tabular tasks [4] [11] . In contrast, gradient-boosted trees or random forests typically require minutes of tuning and larger sample sizes to achieve comparable performance. These empirical gains substantiate TabPFN’s suitability for data-limited and time-sensitive surgical modelling scenarios.

Key advantages include:

To fully realise TabPFN’s transformative potential, we identify ten priority research areas (as illustrated in Figure 4 ):

TabPFN is still an emerging model with limitations that warrant caution in its incorporation into clinical economic workflows. It is concerning that TabPFN, designed with classifiers in mind, may need further restructuring to be usable for regression outputs, which are predominantly utilised in cost modelling and budget impact analyses [2] [4] . In practice, TabPFN’s classification architecture can be adapted for regression by modifying the output layer to predict continuous values rather than discrete class probabilities and by substituting cross-entropy with mean-squared or mean-absolute error loss functions. For instance, when estimating procedure-specific cost distributions, the model can output a continuous cost value per patient episode, enabling simulation of aggregated hospital budget impacts through Monte Carlo sampling. Such adaptation preserves TabPFN’s few-shot learning advantages while supporting continuous economic variables. Compared to tree-based models and explainable boosting machines, its interpretability is weaker, which may diminish trust from clinicians or policymakers in multilateral high-stakes decisions [10] . In addition, while lacking the need for extensive retraining is a beneficial feature of TabPFN’s zero-shot inference, the competing reduction in task-specific optimisation may limit its usefulness in nuanced or domain-specific applications where predictive granularity is essential [2] [10] . The model’s validation on a diverse range of healthcare datasets is sparse, and a thorough evaluation of its robustness to dataset shift, adversarial noise, and variances in data quality triggered by real-world health systems is still lacking [6] [18] [19] . Another potential limitation lies in biases originating from TabPFN’s synthetic pre-training data, which may inadequately represent demographic or procedural diversity in surgical populations. This could result in systematic over- or under-estimation of economic parameters for minority or atypical subgroups. A feasible mitigation strategy involves domain-adaptive fine-tuning using small, institution-specific datasets to recalibrate prior distributions, thereby aligning learned representations with real-world surgical characteristics while maintaining generalisability.

The path to deploying TabPFN in clinical environments is not without challenges. Regulatory approval processes remain conservative, focusing on safety and effectiveness rather than innovation [20] . To gain acceptance as an AI/ML-based Software as a Medical Device (SaMD), TabPFN will need to demonstrate transparency, reproducibility, and performance stability under evolving clinical conditions, as expected under frameworks set by the United States Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA) [20] . In addition, fragmented healthcare IT infrastructures pose significant barriers to data integration and model interoperability [18] . Despite its low computational demands, TabPFN still requires investment in data quality assurance, governance, and validation protocols to ensure safe and effective implementation [19] . Furthermore, TabPFN’s probabilistic output distribution allows derivation of confidence intervals and credible intervals consistent with ISPOR’s Good Practice Task Force guidance on uncertainty characterisation in cost-effectiveness analysis [7] [8] . Its capacity for calibrated posterior probability estimation also aligns with FDA’s SaMD Action Plan emphasis on transparent uncertainty quantification for adaptive algorithms [20] [21] . Integrating these uncertainty estimates directly into sensitivity analyses and scenario simulations enhances decision robustness and regulatory acceptability.

In the context of public health or clinical decision-making, the use of TabPFN-based tools may require strict adherence to the regulatory framework of Software as a Medical Device (SaMD) as delineated by the FDA or the TGA [20] [21] . Risks associated with the use of machine learning or software incorporated into the decision-making processes for advanced diagnostics, therapy, and management may require evaluation prior to entry into the market, risk classification, and perpetual evaluation even after market entry [22] . As highlighted in the FDA’s SaMD action plan, transparency, consistency in performance, and management over time for adaptive algorithms using “Predetermined Change Control Plans” are critical [21] . Correspondingly, the TGA’s regulatory guidance emphasises the importance of explainability, traceability, regulation, and the essential element of human oversight for medical technologies based on artificial intelligence [21] . Though TabPFN may not be directly clinically oriented, any integration of systems into a patient’s or healthcare institution’s economic decision-making systems would demand these requirements to be fulfilled. This underscores the importance of early incorporation of validation frameworks, model explainability frameworks, and use documentation in the translational development of health economic systems based on TabPFN. Thus, the integration of TabPFN in health economic pipelines requires the integration of thorough evaluation frameworks, monitoring strategies post-deployment, and compliance with regulatory frameworks concerning explainability and fairness for AI systems in clinical settings [18] [20] .

TabPFN constitutes a fundamental enhancement in the predictive modelling of surgical health economics. Its design deliberately mitigates the principal shortcomings of conventional methodologies, delivering exceptional performance on small, heterogeneous datasets while simultaneously furnishing robust uncertainty quantification and transparent interpretability. By accommodating personalised cost-effectiveness analyses, iterative budget impact modelling, and real-time resource forecasting, the framework renders analyses once deemed impracticable now commonplace. This capability promises to redefine the practice of health economic evaluation, both at the individual patient level and within broader public health systems, in alignment with the global movement toward precision medicine and asynchronous, evidence-driven clinical decision support. Realising this promise will necessitate synergistic collaboration among computational scientists, surgeons, health economists, regulators, and policy-makers. To fully leverage TabPFN’s translational potential, future work must focus on domain-specific validation, SaMD-aligned deployment protocols, and equitable integration across healthcare systems. With these foundations, TabPFN can catalyse a forward-looking paradigm of precision health economics characterised by analytical pre-eminence and tangible clinical and societal value.